Armenia Medical Device Registration Timeline: 60 and 30 Working Days and the Real Project Duration
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The registration timeline published by the Ministry of Health of Armenia consists of four segments: expert assessment by the reference member state of up to 60 working days from acceptance of the application, harmonization of the expert opinion by the recognizing member state of up to 30 working days, a registration decision within 10 working days after the completion of harmonization, and preparation and issuance of the registration certificate of up to 10 working days. The key warning from GRZAN: the roughly 110 working days covered by these four segments represent only the clock of the authorities; the periods for the applicant to respond to deficiency requests, to conduct tests, to undergo production inspections and to deliver inspection reports are all excluded, so the real project duration is typically 2 to 3 times the official clock.
2. Legal basis
| Regulation | Document number | Publication date (effective date) | Provisions |
|---|---|---|---|
| Rules for the Registration and Assessment of Medical Devices in Terms of Safety, Quality and Effectiveness | Decision No. 46 of the Council of the Eurasian Economic Commission, 2016-02-12 | Amended by Council Decision No. 144 of 2021-12-24 | Article 14 (excluded periods) |
| Official webpage of the Ministry of Health of Armenia, State Registration of Medical Devices | — | current | Procedure and timelines |
| Requirements for the Implementation, Maintenance and Assessment of Quality Management Systems for Medical Devices According to Potential Use Risks | Decision No. 106 of the Council of the Eurasian Economic Commission, 2017-11-10 | Amended by Council Decision No. 43 of 2026-04-27 (effective 2026-06-18) | Provisions on inspection time limits |
3. Expert insights
Insight 1: Article 14 lists four categories of excluded periods, which is the true source of schedule slippage. The provision states that when the authorities, meaning the expert organizations, calculate the procedural time limits, the following periods are not counted: a) the period from the date on which the authorized body of the reference state issues a request or notification to the applicant, requiring the elimination of detected violations and/or the submission of missing documents, or the submission of a copy of the payment receipt for the harmonization procedure of the recognizing state, until the date of receipt of the reply to that request or notification; b) the period required to organize and conduct a production inspection, where a production inspection is carried out within the registration and assessment procedure; c) the period required for the inspection organization to send the report on the production inspection results to the authorized body, where the inspection is not organized by the authorized body itself; and d) the period needed to consult the applicant on whether it is necessary to refer a matter to the Advisory Board on Medical Devices of the Board of the Eurasian Economic Commission. GRZAN points out that item a is the most common black hole: the official clock stops for exactly as long as the deficiency response is delayed.
Insight 2: the official Armenian presentation and the Union rules differ in granularity. The Ministry of Health of Armenia publishes a four-segment overview, while inside the Union rules there are additional stages such as acceptance checking, deficiency notifications, assessment, production inspections and the issuance of expert opinions. GRZAN points out that companies should build their external commitments on the official Armenian four segments, while managing the internal schedule with a Gantt chart built on the granular stages of the Union rules (a practical estimate: the specific working-day counts of the granular stages differ across member state practice, and the actual notifications of the competent authority prevail).
Insight 3: the testing periods fall entirely outside the clock. The Ministry of Health of Armenia states explicitly that the periods required to conduct technical tests, biological tests and clinical trials, as well as the periods required for the assessment or audit of the quality management system, are not counted within the registration time limit and depend on the complexity of the medical device. GRZAN points out that this makes the testing cycle, which typically lasts several months, a stage that is in series with the official clock; it cannot be netted out in parallel when building the project schedule.
Insight 4: after 2026 the production inspection period has a hard cap. Under Decision No. 43 of 2026, the duration of both periodic and unscheduled inspections must not exceed 90 working days, and the application for a periodic inspection must be submitted at least 90 working days before the previous inspection report expires. GRZAN points out that Decision No. 106 already provided that the total period for organizing and conducting a production inspection, counted from the decision to start the production inspection, must not exceed 90 working days; the 2026 amendment extends this cap to periodic and unscheduled inspections and quantifies the advance filing requirement at 90 working days, which significantly improves scheduling certainty.
Insight 5: the four-segment timeline overlaid with the excluded items.
| Stage | Official clock | Counted | Typical real duration |
|---|---|---|---|
| Expert assessment by the reference state | up to 60 working days | counted | recalculated after deficiency responses |
| Harmonization of the expert opinion by recognizing states | up to 30 working days | counted | includes submission of payment receipts |
| Registration decision | within 10 working days | counted | — |
| Preparation and issuance of the certificate | up to 10 working days | counted | — |
| Deficiency responses by the applicant | — | not counted | determines the total project duration |
| Technical, biological and clinical trials | — | not counted | depends on product complexity |
| Production inspection | up to 90 working days | not counted | depends on the number of manufacturing sites |
4. Practical recommendations
- Use the official clock for external commitments and the total duration for internal scheduling: write in contracts and launch commitments that the official clock is about 110 working days from acceptance, and reserve 2 to 3 times that period in the internal Gantt chart.
- Make deficiency response the highest-priority process: establish a service level for deficiency responses with the target of replying within 10 working days of receiving the request, so as to shorten the periods during which the clock is stopped.
- Front-load the testing: complete technical, biological and clinical testing before the formal submission, to avoid long clock stoppages caused by tests added after filing.
- Schedule production inspections off-peak: use the 90-working-day cap introduced by the 2026 amendment and write the advance filing window for periodic inspections, itself 90 working days, into the annual quality plan.
5. Verification checklist
- □ The official four-segment Armenian timeline, 60 / 30 / 10 / 10 working days, has been recorded.
- □ The four excluded periods a to d of Article 14 have been flagged in the project plan.
- □ A service level for deficiency responses has been established with a named owner.
- □ Completion or scheduling of technical, biological and clinical testing before submission has been confirmed.
- □ The 90-working-day cap for production inspections has been written into the schedule.
- □ The 90-working-day advance filing for periodic inspections has been written into the annual quality plan.
- □ The distinction between the official clock and the total project duration has been reflected in contracts and launch commitments.
Regulatory information verified as of October 30, 2026.
GRZAN service note. GRZAN helps manufacturers build realistic registration schedules for the Eurasian Economic Union and Armenia, covering official-clock analysis, deficiency response service levels, testing front-loading and inspection planning. Regulatory monitoring is updated continuously and confirmed against the official sources cited above. For inquiries, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us